What health benefits do GLP-1 medications offer beyond weight loss?

The strongest and most concrete benefit lies in cardiovascular protection. In people with type 2 diabetes, GLP-1 medications reduce the risk of a heart attack, stroke, or death from heart disease by 14%. The chance of dying from any cause falls by 12%. Hospitalisation due to heart failure becomes 11% less likely. These are not laboratory findings: they come from a meta-analysis of eight large randomised trials involving more than 60,000 patients combined.

The kidneys also benefit in a measurable way. In type 2 diabetes, the risk of serious kidney damage, such as a sharp decline in kidney function or the need for dialysis, falls by 21%. GLP-1 medications also lower blood pressure, blood sugar, and fat metabolism after meals. Those effects likely explain part of the protection, although the precise contribution of each effect has not yet been fully disentangled.

For the liver, there is a randomised phase 2 study in patients with non-alcoholic fatty liver disease (a serious, chronic liver inflammation unrelated to alcohol use). Liraglutide, one of the GLP-1 agents, reduced liver fat and liver inflammation in that study. The results are promising, but it is still a relatively small study; larger confirmatory evidence is not yet available.

Beyond the heart, kidneys, and liver, there are smaller indications of broader effects. Several small clinical studies suggest improvement of motor symptoms in Parkinson's disease, better brain glucose metabolism in Alzheimer's disease, fewer depressive symptoms, and possibly less relapse in addictions. These are preliminary findings from a limited number of studies. They are interesting but nowhere near solid enough yet to support practical recommendations.

Safety: the large meta-analysis showed no increased risk of serious low blood sugar, retinal damage, or pancreatic cancer. The most common side effects are gastrointestinal complaints. The cardiovascular, kidney, and liver benefits have so far been studied in people with type 2 diabetes; whether the same effect sizes apply to people without diabetes or with a different risk profile has not yet been adequately investigated.